Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This is a pivotal phase II, multicenter, open-label trial, designed to compare the efficacy
of exemestane versus anastrozole as a first line treatment for advanced breast cancer. One
hundred postmenopausal patients, with metastatic, positive hormone receptor breast cancer
will be enrolled in this trial.